Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Why methylation is not a marker predictive of response to hypomethylating agents.

Haematologica - 1 Apr 2014

Voso Maria Teresa, Santini Valeria, Fabiani Emiliano, Fianchi Luana, Criscuolo Marianna, Falconi Giulia, Guidi Francesco, Hohaus Stefan, Leone Giuseppe

Abstract excerpt

The azanucleotides azacitidine and decitabine have been shown to induce hematologic response and prolong survival in higher-risk myelodysplastic syndromes. They are inhibitors of DNA methyltransferase-1 and induce DNA-hypomethylation. Induction of apoptosis is also clinically relevant, in particular during the first treatment cycles, when cytopenia is a frequent side-effect. Since the hypomethylating effect is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biomarkers

Share to DNA Methylation

Share to DNA Modification Methylases

Share to Epigenesis, Genetic

Share to Myelodysplastic Syndromes

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 24688109
DOI: 10.3324/haematol.2013.099549
PMCID: PMC3971070

Genes

IDH1
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Why methylation is not a marker predictive of response to hypomethylating agents.PMID 24688109Read ↗

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.Semantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survivalSemantic proximity Read ↗

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read ↗

The use of hypomethylating agents in the treatment of hematologic malignanciesSemantic proximity Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

Targeting DNA MethylationSemantic proximity Read ↗

Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomesSemantic proximity Read ↗

Clinical development of demethylating agents in hematologySemantic proximity Read ↗

DNA Hypermethylation of Myeloid Cells, A Novel Therapeutic Target in MDS and AMLSemantic proximity Read ↗

Azacytidine causes complex DNA methylation responses in myeloid leukemiaSemantic proximity Read ↗

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell lineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.